About TolerogenixX
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.
Press releases
Press
TolerogenixX secures seed funding and completes Phase I clinical trial
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. In a Phase I clinical trial, the technique was successfully employed during kidney transplants. Patients who received transplants became tolerant of the donated organ. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance thi
Info & Contact
Address
TolerogenixX GmbH
Im Neuenheimer Feld 162
69120 Heidelberg
Im Neuenheimer Feld 162
69120 Heidelberg
In portfolio
21. Dec 2016
Sector
Ulrike Kalapis
Investment Manager